350 related articles for article (PubMed ID: 15127320)
61. Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches.
Nordt TK; Bode C
Semin Thromb Hemost; 2000; 26(5):495-501. PubMed ID: 11129405
[TBL] [Abstract][Full Text] [Related]
62. [Fibrinolytic system in bronchial asthma after prednisone treatment].
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Pol Merkur Lekarski; 2000 Jan; 7(43):9-11. PubMed ID: 10765644
[TBL] [Abstract][Full Text] [Related]
63. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
[TBL] [Abstract][Full Text] [Related]
64. [The insulin resistance syndrome and fibrinolysis disorders].
Okapcová J; Hrnciar J
Vnitr Lek; 1997 Jun; 43(6):373-8. PubMed ID: 9601868
[TBL] [Abstract][Full Text] [Related]
65. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
66. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
[TBL] [Abstract][Full Text] [Related]
67. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
68. Regular alcohol intake and fibrinolysis.
van Golde PM; Hart HCh; Kraaijenhagen RJ; Bouma BN; van de Wiel A
Neth J Med; 2002 Aug; 60(7):285-8. PubMed ID: 12430575
[TBL] [Abstract][Full Text] [Related]
69. Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.
Sato Y; Dong J; Imagawa S; Ishimori N; Furumoto T; Tsutsui H; Sobel BE; Fujii S
Coron Artery Dis; 2008 Aug; 19(5):355-61. PubMed ID: 18607173
[TBL] [Abstract][Full Text] [Related]
70. Short-term intensive glycemic control improves vibratory sensation in type 2 diabetes.
Fujita Y; Fukushima M; Suzuki H; Taniguchi A; Nakai Y; Kuroe A; Yasuda K; Hosokawa M; Yamada Y; Inagaki N; Seino Y
Diabetes Res Clin Pract; 2008 Apr; 80(1):e16-9. PubMed ID: 18262304
[TBL] [Abstract][Full Text] [Related]
71. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Sakurai S; Jojima T; Iijima T; Tomaru T; Usui I; Aso Y
J Diabetes Complications; 2020 Nov; 34(11):107703. PubMed ID: 32883567
[TBL] [Abstract][Full Text] [Related]
72. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
73. Effects of short-term exercise training on plasminogen activator inhibitor (PAI-1).
Bodary PF; Yasuda N; Watson DD; Brown AS; Davis JM; Pate RR
Med Sci Sports Exerc; 2003 Nov; 35(11):1853-8. PubMed ID: 14600550
[TBL] [Abstract][Full Text] [Related]
74. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
Vicari AM; Viganó D'Angelo S; Testa S; Comi G; Galardi G; Orsi E; D'Angelo A
Horm Metab Res; 1992 Nov; 24(11):516-9. PubMed ID: 1452117
[TBL] [Abstract][Full Text] [Related]
75. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction.
Gray RP; Mohamed-Ali V; Patterson DL; Yudkin JS
Thromb Haemost; 1995 Feb; 73(2):261-7. PubMed ID: 7792741
[TBL] [Abstract][Full Text] [Related]
76. Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.
Bladbjerg EM; Henriksen JE; Akram S; Gram J
Diabetes Obes Metab; 2012 May; 14(5):447-53. PubMed ID: 22151836
[TBL] [Abstract][Full Text] [Related]
77. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
78. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
Dewerchin M; Collen D; Lijnen HR
Thromb Haemost; 2001 Aug; 86(2):640-6. PubMed ID: 11522016
[TBL] [Abstract][Full Text] [Related]
79. [Changes of fibrinolysis during labour with and without aprotinin application].
Kühnert M; Stein W; Tekesin I; Hellmeyer L; Schmidt S
Z Geburtshilfe Neonatol; 2003; 207(3):90-100. PubMed ID: 12891467
[TBL] [Abstract][Full Text] [Related]
80. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
